Browsing Tag
Novo Nordisk
103 posts
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
GLP-1 receptor agonists show promise in cutting death and heart risk in psoriasis patients
Discover how GLP-1 drugs may slash death and heart risks in psoriasis patients, reshaping care strategies beyond skin treatment.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Novo Nordisk eyes FDA approval for high-dose 7.2mg Wegovy after STEP UP trial shows 21% weight loss
Novo Nordisk seeks U.S. approval for 7.2mg Wegovy after 21% average weight loss in trials. Can it outpace Eli Lilly’s Zepbound in the obesity drug race?
Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war
CVS Caremark faces a lawsuit after dropping Eli Lilly’s Zepbound from coverage. Explore patient, investor, and payer implications in the GLP-1 market battle.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Can oral GLP-1 pills match injected options in efficacy and patient adherence? What’s next for Wegovy and Rybelsus
Can oral GLP-1 drugs like Wegovy and orforglipron match injectables in weight loss and adherence? Discover what’s next in chronic obesity treatment.
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.